Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways

Immune responses against gene therapy products limit its therapeutic efficacy and present a safety risk. Identification of agents that blunt immune reactions may aid in developing novel immunomodulatory therapies. Fingolimod (FTY720) is an FDA approved immunomodulatory drug for treating multiple scl...

Descripción completa

Detalles Bibliográficos
Autores principales: Baer, Alan, Colon-Moran, Winston, Bhattarai, Nirjal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053412/
https://www.ncbi.nlm.nih.gov/pubmed/30026610
http://dx.doi.org/10.1038/s41598-018-29355-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053412/
https://www.ncbi.nlm.nih.gov/pubmed/30026610
http://dx.doi.org/10.1038/s41598-018-29355-0

Ejemplares similares